
Canada has a world-class reputation for developing next-generation therapies. But a growing gap between scientific breakthroughs and patient access threatens to undermine that strength.
A gene therapy designed to halt a rare condition causing vision loss was approved by Health Canada. Yet one parent still faced years of uncertainty over whether her children could receive it, and if the provincial health system would pay for it.
A system designed for 20th-century drugs
This gap is becoming a defining challenge for Canadian healthcare. Cell and gene therapies and other forms of regenerative medicine are moving from laboratories into clinical care. They offer the possibility of treating or even curing diseases that medicine has historically only been able to manage.
But these 21st-century medicines are being evaluated by a system designed for 20th-century drugs. This system struggles with the unique challenges of living therapies and rare diseases.
A Stem Cell Network report highlights the problem. It examined three therapies connected to Canadian research: a gene therapy for a rare fatal disease in newborns, a tissue-engineered skin replacement for severe burns, and an individualized treatment for a rare pediatric neurodevelopmental disorder.
A fragmented system creates delays
Living therapies currently move through regulation, health technology assessment, pricing, reimbursement, and health system adoption as separate steps, managed by different entities. This fragmentation leads to delays and even roadblocks for patients.
For a newborn with a rapidly progressing genetic disease, such delays can be devastating, closing the treatment window.
A call for modernization
For families like Charmain Brown’s, the distinction between a medical breakthrough and accessible treatment is stark. A therapy sitting on the far side of a regulatory or reimbursement process may as well not exist for the patient who cannot access it.
Addressing Challenges in Regenerative Medicine and Rare Diseases
Regenerative medicine and rare diseases present unique challenges to the current system. In these cases, the therapeutic process is integral to the treatment, and traditional large-scale trials may be impractical due to the limited number of patients. Some treatments are even tailored for a single individual.